Company

Kuros Biosciences AG

Headquarters: Schlieren, Switzerland

Employees: 51

CEO: Prof. Joost D. de Bruijn B.S., Ph.D., B.Sc. Ph.D.

SIX: KURN -5.34%

Market Cap

CHF163.1 Million

CHF as of Jan. 1, 2024

US$193.7 Million

Market Cap History

Kuros Biosciences AG market capitalization over time

Evolution of Kuros Biosciences AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Kuros Biosciences AG

Detailed Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Kuros Biosciences AG has the following listings and related stock indices.


Stock: SIX: KURN wb_incandescent

Details

Headquarters:

Wagistrasse 25

Schlieren, 8952

Switzerland

Phone: 41 44 733 4747

Fax: 41 44 733 4740